In silico studies to assess preclinical cardiac safety

Why conduct an in silico study?

An in silico study uses modelling and simulation techniques to evaluate drug safety. In silico models allow the reconstruction of the electrophysiological activity within a heart cell.  The Comprehensive in vitro Proarrhythmia Assay (CiPA) is a novel safety screening proposal intended to replace the 2005 regulatory strategy recommended by the International Conference of Harmonization S7B guideline. One of the 3 main components of the CiPA initiative is in silico integration of the data obtained from ion channel assays in order to determine the net effects on cardiac action potential.

Why choose PhysioStim for your in silico study?

PhysioStim has established preferential and strong partnerships with top level partners in order to expertly guide your in silico assay.

Advice from our expert scientists

In order to complete the CiPA pathway, PhysioStim recommends completing your in silico study with additional in vitro tests:

Need help with your preclinical safety assays?

Don’t hesitate to contact us